1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a pro-neurotoxicant that must be metabolized to 1-methyl-4-phenylpyridinium (MPP(+)) and taken up into striatal dopaminergic neurons to produce neurodegeneration. Recently, we showed wide genetic variability in MPTP-associated neuronal damage in a panel of recombinant inbred mouse strains. Here we examined the amount of MPP(+) produced in the striatum in the same strains of inbred BXD mice. This allowed us to determine if the differences in the dopaminergic neurotoxicity and associated astrogliosis among the BXD mouse strains were due to differential metabolism of MPTP to MPP(+). Using the same BXD mouse strains examined previously (Jones et al., 2013) we found that the extent of the st...
Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes loss of dopaminergic neurons ...
Evidence for involvement of cytochrome P450 2E1 in the MPTP-induced mouse model of PD has been repor...
The dose- and time-dependent changes of in vivo radioligand binding to the neuronal membrane dopamin...
Continuing our previous work in which we showed wide-ranging strain differences in MPTP neurotoxicit...
The effects of MPTP treatment (4 × 10 mg/kg, 2-h intervals) on in vivo striatal binding of (+)-α-[ 3...
<p>The degree of dopaminergic neurodegeneration caused by MPTP administration was evaluated by exami...
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces motor and nonmotor dysfun...
AbstractThis review summarizes advances in our understanding of the biochemical events which underli...
AbstractChemical reactions of MPDP+, a recognized intermediate in the metabolic conversion of the ne...
We investigated the level of dopamine in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin...
The role of genetics in the etiology of PD has been controversial, but recent studies provide strong...
We have used mouse and non-human primate models of Parkinson's Disease to analyze neuronal dysfuncti...
Swiss mice were given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 25 mg/kg/day, for 5 conse...
The neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been proposed to be...
The risk of developing Parkinson’s disease (PD) is due to the nonorthogonal effects of numerous gene...
Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes loss of dopaminergic neurons ...
Evidence for involvement of cytochrome P450 2E1 in the MPTP-induced mouse model of PD has been repor...
The dose- and time-dependent changes of in vivo radioligand binding to the neuronal membrane dopamin...
Continuing our previous work in which we showed wide-ranging strain differences in MPTP neurotoxicit...
The effects of MPTP treatment (4 × 10 mg/kg, 2-h intervals) on in vivo striatal binding of (+)-α-[ 3...
<p>The degree of dopaminergic neurodegeneration caused by MPTP administration was evaluated by exami...
The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induces motor and nonmotor dysfun...
AbstractThis review summarizes advances in our understanding of the biochemical events which underli...
AbstractChemical reactions of MPDP+, a recognized intermediate in the metabolic conversion of the ne...
We investigated the level of dopamine in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin...
The role of genetics in the etiology of PD has been controversial, but recent studies provide strong...
We have used mouse and non-human primate models of Parkinson's Disease to analyze neuronal dysfuncti...
Swiss mice were given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 25 mg/kg/day, for 5 conse...
The neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been proposed to be...
The risk of developing Parkinson’s disease (PD) is due to the nonorthogonal effects of numerous gene...
Exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes loss of dopaminergic neurons ...
Evidence for involvement of cytochrome P450 2E1 in the MPTP-induced mouse model of PD has been repor...
The dose- and time-dependent changes of in vivo radioligand binding to the neuronal membrane dopamin...